Previous 10 | Next 10 |
Ideaya Biosciences ( NASDAQ: IDYA ) said it started enrollment in a phase 2 trial of darovasertib as monotherapy in neo-adjuvant and adjuvant settings in patients with primary, non-metastatic uveal melanoma (UM). UM is a type of eye cancer. In one group patients with large tu...
IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma PR Newswire - Initiated Phase 2 clinical trial evaluating Darovasertib as neoadjuvant treatment of uveal melanoma ...
IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161 PR Newswire - Targeting to initiate dosing of Phase 1 clinical trial in Q1 2023 to evaluate IDE161 in patients having tumors with HRD, including BRCA1/2-mu...
Summary IDEAYA caught a bid in the back end of FY22' as investors began to take notice of advancements in its clinical pipeline. The rally seems to have flattened into the new year, so we wanted to check if there's scope for it to extend further. The company's investigational compou...
IDEAYA Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused prec...
IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board PR Newswire - Dr. Karlene Cimprich , Ph.D. ( Stanford University ), is a leading scientist in replication stress mechanisms and regulati...
IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Collaboration with GSK PR Newswire Selected a potential first-in-class Pol Theta Helicase development candidate in collaboration with GSK Observed comple...
The biotech bear market has been particularly hard on Precision Oncology companies - particularly those that came to market on the back of lucrative IPOs. Ideaya IPO'd in 2019, raising a modest $55m, and it continues to trade above its IPO price of $10, which is rare. Shares hit a hig...
IDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , June 8, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology comp...
Roth Capital Partners is raising its price target on Ideaya Biosciences (NASDAQ:IDYA) to a Street high of $46 from $42 (341% upside based on Monday's close) while maintaining a buy rating. Analyst Zegbeh Jallah said that the company is well positioned following the recent release of Q1 2...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NASDAQ Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery an...
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...